<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30066497</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>25</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">2045-7634</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>7</Volume>                    <Issue>9</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                    </PubDate>                </JournalIssue>                <Title>Cancer medicine</Title>                <ISOAbbreviation>Cancer Med</ISOAbbreviation>            </Journal>            <ArticleTitle>Clinical benefit of treatment with eribulin mesylate for metastatic triple-negative breast cancer: Long-term outcomes of patients treated in the US community oncology setting.</ArticleTitle>            <Pagination>                <MedlinePgn>4371-4378</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1002/cam4.1705</ELocationID>            <Abstract>                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Real-world data are critical to demonstrate the consistency of evidence and external generalizability of randomized controlled trials (RCTs). This study examined characteristics and outcomes of metastatic triple-negative breast cancer (mTNBC) patients treated with eribulin mesylate at community oncology practices in the United States.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Physicians identified mTNBC patients initiating eribulin between 1 January 2011 and 1 January 2014 and abstracted data into an electronic case report form (eCRF). Eribulin treatment in the metastatic setting was categorized as early use (EU, first-/second-line) and late use (LU, third-line or later). Patient characteristics, overall survival (OS), disease response (per treating physician), and adverse events (AEs) rates in each group, respectively, are reported.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall 252 eCRFs were completed: 125 (49.6%) EU and 127 (50.4%) LU. The median age at metastatic diagnosis was 53 years and 42.1% were stage IV at their initial diagnosis. The median duration of follow-up from the initiation of first-line treatment was 24 months. Rates of disease response (complete or partial per treating physician) were 69.9% in the EU group and 48.8% in the LU group. The five most commonly reported adverse events during eribulin were as follows: fatigue (65.1%), weakness (40.1%), decreased appetite (32.5%), neutropenia (31.0%), and leukopenia (27.4%). Discontinuation of eribulin due to AE was observed in 4.0% of patients. Median OS from initiation of eribulin was 23.0 months (95% CI: 18.7-27.3) among EU and 14.7 (95% CI: 12.6-16.9) among LU.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In the real-world eribulin-treated mTNBC, patients have more sites of metastatic disease and exposure to greater numbers of prior therapies compared to RCTs. The median OS of 14.7 months among LU patients is consistent with, and slightly longer than the 13.1 months and 14.4 months reported in the EMBRACE and Study 301 clinical trials, respectively.</AbstractText>                <CopyrightInformation>© 2018 The Authors. Cancer Medicine published by John Wiley &amp; Sons Ltd.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Mougalian</LastName>                    <ForeName>Sarah S</ForeName>                    <Initials>SS</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-8837-1425</Identifier>                    <AffiliationInfo>                        <Affiliation>Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Copher</LastName>                    <ForeName>Ronda</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Eisai Inc., Woodcliff Lake, New Jersey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kish</LastName>                    <ForeName>Jonathan K</ForeName>                    <Initials>JK</Initials>                    <AffiliationInfo>                        <Affiliation>Cardinal Health Specialty Solutions, Dallas, Texas.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>McAllister</LastName>                    <ForeName>Lindsay</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Cardinal Health Specialty Solutions, Dallas, Texas.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Zhixiao</ForeName>                    <Initials>Z</Initials>                    <AffiliationInfo>                        <Affiliation>Eisai Inc., Woodcliff Lake, New Jersey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Broscious</LastName>                    <ForeName>Mary</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Cardinal Health Specialty Solutions, Dallas, Texas.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Garofalo</LastName>                    <ForeName>David</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Cardinal Health Specialty Solutions, Dallas, Texas.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Radtchenko</LastName>                    <ForeName>Janna</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Cardinal Health Specialty Solutions, Dallas, Texas.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Feinberg</LastName>                    <ForeName>Bruce A</ForeName>                    <Initials>BA</Initials>                    <AffiliationInfo>                        <Affiliation>Cardinal Health Specialty Solutions, Dallas, Texas.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <Agency>Eisai, Inc.</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>07</Month>                <Day>31</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Cancer Med</MedlineTA>            <NlmUniqueID>101595310</NlmUniqueID>            <ISSNLinking>2045-7634</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>J Cancer. 2014 Mar 20;5(5):320-7</RefSource>                <PMID Version="1">24723974</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Breast Cancer Rep. 2013 Mar 1;5(1):42-50</RefSource>                <PMID Version="1">23440080</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2011 Mar 12;377(9769):914-23</RefSource>                <PMID Version="1">21376385</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncology (Williston Park). 2017 Feb 15;31(2):130-7</RefSource>                <PMID Version="1">28205193</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Med. 2018 Sep;7(9):4371-4378</RefSource>                <PMID Version="1">30066497</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2014 Jul;146(2):321-8</RefSource>                <PMID Version="1">24699910</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2014 Dec;148(3):553-61</RefSource>                <PMID Version="1">25381136</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2009 May;115(2):423-8</RefSource>                <PMID Version="1">18543098</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2015 Jun 10;33(17):1902-9</RefSource>                <PMID Version="1">25847936</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Breast Cancer. 2009 Feb;9(1):29-33</RefSource>                <PMID Version="1">19299237</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2007 May 1;109(9):1721-8</RefSource>                <PMID Version="1">17387718</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2013 Nov 1;31(31):3997-4013</RefSource>                <PMID Version="1">24101045</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2015 Feb 20;33(6):594-601</RefSource>                <PMID Version="1">25605862</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mayo Clin Proc. 2009 Jun;84(6):533-45</RefSource>                <PMID Version="1">19483170</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74</RefSource>                <PMID Version="1">11553815</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Biol Ther. 2015;16(12):1746-53</RefSource>                <PMID Version="1">26466918</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">eribulin</Keyword>            <Keyword MajorTopicYN="N">metastatic breast cancer</Keyword>            <Keyword MajorTopicYN="N">real-world</Keyword>            <Keyword MajorTopicYN="N">survival</Keyword>            <Keyword MajorTopicYN="N">triple negative</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>03</Month>                <Day>27</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>06</Month>                <Day>19</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>06</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>2</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>2</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>2</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30066497</ArticleId>            <ArticleId IdType="doi">10.1002/cam4.1705</ArticleId>            <ArticleId IdType="pmc">PMC6144147</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>